Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

24 terminated/withdrawn out of 96 trials

Success Rate

41.5%

-45.1% vs industry average

Late-Stage Pipeline

18%

17 trials in Phase 3/4

Results Transparency

141%

24 of 17 completed trials have results

Key Signals

28 recruiting24 with results22 terminated

Enrollment Performance

Analytics

Phase 1

46(49.5%)

Phase 2

30(32.3%)

Phase 3

15(16.1%)

Phase 4

2(2.2%)

93Total

Phase 1(46)

Phase 2(30)

Phase 3(15)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (96)

Showing 20 of 96 trials

NCT07564141Phase 3Recruiting

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Role: lead

NCT03625037Phase 1Active Not Recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Role: lead

NCT07166094Phase 3Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

Role: lead

NCT07539311Phase 2Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

Role: lead

NCT03917381Phase 1Active Not Recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Role: lead

NCT06635824Phase 3Active Not Recruiting

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Role: lead

NCT07387068Phase 1Recruiting

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

Role: lead

NCT04542824Phase 1Active Not Recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Role: lead

NCT04623541Phase 1Active Not Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Role: lead

NCT07384715Phase 1Recruiting

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Role: lead

NCT07695831Phase 1Not Yet Recruiting

A Phase 1 Trial of GEN1119 in Participants With Solid Tumors

Role: lead

NCT06191744Phase 3Active Not Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Role: lead

NCT04663347Phase 1Active Not Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Role: lead

NCT07225270Phase 3Recruiting

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Role: lead

NCT07702032Phase 3Recruiting

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer

Role: lead

NCT06057038Phase 1Active Not Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Role: lead

NCT04083599Phase 1Active Not Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Role: lead

NCT05579366Phase 1Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Role: lead

NCT07288177Phase 2Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer